↓ Skip to main content

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

Overview of attention for article published in PLOS ONE, June 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs
2 blogs

Citations

dimensions_citation
49 Dimensions

Readers on

mendeley
39 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
Published in
PLOS ONE, June 2010
DOI 10.1371/journal.pone.0010941
Pubmed ID
Authors

David M. Lucas, Lapo Alinari, Derek A. West, Melanie E. Davis, Ryan B. Edwards, Amy J. Johnson, Kristie A. Blum, Craig C. Hofmeister, Michael A. Freitas, Mark R. Parthun, Dasheng Wang, Amy Lehman, Xiaoli Zhang, David Jarjoura, Samuel K. Kulp, Carlo M. Croce, Michael R. Grever, Ching-Shih Chen, Robert A. Baiocchi, John C. Byrd

Abstract

While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 38 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 28%
Student > Ph. D. Student 7 18%
Student > Bachelor 5 13%
Professor > Associate Professor 3 8%
Student > Doctoral Student 2 5%
Other 5 13%
Unknown 6 15%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 11 28%
Agricultural and Biological Sciences 11 28%
Medicine and Dentistry 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Chemistry 2 5%
Other 1 3%
Unknown 8 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2011.
All research outputs
#1,685,163
of 22,659,164 outputs
Outputs from PLOS ONE
#21,832
of 193,435 outputs
Outputs of similar age
#5,831
of 95,943 outputs
Outputs of similar age from PLOS ONE
#96
of 688 outputs
Altmetric has tracked 22,659,164 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 193,435 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,943 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 688 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.